Lixivaptan BALANCE study is a 650-patient Phase III, global, multi-center, randomized, placebo-controlled, double-blind, study of lixivaptan for hyponatremia in patients with heart failure. The primary objective is to evaluate the safety and effectiveness of lixivaptan, when compared to the placebo, in increasing serum sodium from baseline in heart failure patients with hyponatremia. In previous studies, lixivaptan improved blood sodium levels, lowered body weight and increased urine volume. Those studies suggest that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with heart failure, Syndrome of Inappropriate Anti-Diuretic Hormone(SIADH), and Liver Cirrhosis with
Serum (blood) small molecules to cells. Like many other mass nouns, the word "serum" can be pluralized when used in certain senses. To speak of multiple serum specimens from multiple people (each with a unique population of antibodies), physicians sometimes speak of sera (the Latin plural, as opposed to *"serums"). Serum (blood) In blood, the serum () is the component that is neither a blood cell (serum does not contain white blood cells- leukocytes, or red blood cells- erythrocytes), nor a clotting factor; it is the blood plasma not including the fibrinogens. Serum includes all proteins not used in blood clotting and